Mucosal immunotherapy targeting APC in lung disease
- PMID: 40229816
- PMCID: PMC11998460
- DOI: 10.1186/s12950-025-00432-2
Mucosal immunotherapy targeting APC in lung disease
Abstract
Several studies have demonstrated that the pulmonary immune response is primarily facilitated by antigen-presenting cells (APCs), and that both professional and non-professional APCs contribute to overall pulmonary immunity. APCs play unique roles and mechanisms in pathogen elimination and immunomodulation. Mucosal immunity exhibits potential advantages over traditional parenteral immunity in that it stimulates immune defenses in mucosal and systemic tissues, which is important for reducing the burden of lung disease. However, obtaining a comprehensive understanding of the crosstalk between mucosal immunity and APC in the context of various lung diseases remains challenging. This mini-review aimed to elucidate the mechanisms of novel mucosal immunity, targeting APC action during lung infections, allergies, and malignant tumorigenesis. This minreview provides important insights into more effective therapeutic approaches for various lung diseases.
Keywords: APC; Adjuvant; Immune; Lung diseases; Mucosal vaccine.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Competing interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Similar articles
-
Inflammatory cytokines and antigen presenting cell activation.Vet Immunol Immunopathol. 2002 Sep 10;87(3-4):109-21. doi: 10.1016/s0165-2427(02)00042-9. Vet Immunol Immunopathol. 2002. PMID: 12072225 Review.
-
Harnessing the potential of the NALT and BALT as targets for immunomodulation using engineering strategies to enhance mucosal uptake.Front Immunol. 2024 Sep 2;15:1419527. doi: 10.3389/fimmu.2024.1419527. eCollection 2024. Front Immunol. 2024. PMID: 39286244 Free PMC article. Review.
-
The TLR5 Agonist Flagellin Shapes Phenotypical and Functional Activation of Lung Mucosal Antigen Presenting Cells in Neonatal Mice.Front Immunol. 2020 Feb 18;11:171. doi: 10.3389/fimmu.2020.00171. eCollection 2020. Front Immunol. 2020. PMID: 32132997 Free PMC article.
-
Intrapulmonary (i.pulmon.) Pull Immunization With the Tuberculosis Subunit Vaccine Candidate H56/CAF01 After Intramuscular (i.m.) Priming Elicits a Distinct Innate Myeloid Response and Activation of Antigen-Presenting Cells Than i.m. or i.pulmon. Prime Immunization Alone.Front Immunol. 2020 May 7;11:803. doi: 10.3389/fimmu.2020.00803. eCollection 2020. Front Immunol. 2020. PMID: 32457748 Free PMC article.
-
ISCOMATRIX™ adjuvant reduces mucosal tolerance for effective pulmonary vaccination against influenza.Hum Vaccin Immunother. 2015;11(2):377-85. doi: 10.4161/21645515.2014.990859. Hum Vaccin Immunother. 2015. PMID: 25692970 Free PMC article.
References
-
- Zhang Z, Wang Y, Xia L, Zhang Y. Roles of critical amino acids metabolism in the interactions between intracellular bacterial infection and macrophage function. Curr Microbiol. 2024;81:280. - PubMed
-
- Luan H, Horng T. Dynamic changes in macrophage metabolism modulate induction and suppression of Type I inflammatory responses. Curr Opin Immunol. 2021;73:9–15. - PubMed
-
- Vermaelen K, Pauwels R. Pulmonary dendritic cells. Am J Respir Crit Care Med. 2005;172:530–51. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous